PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Advanced Oncotherapy (AVO)

Advanced Oncotherapy

Further re Subscription and Issue of Equity
RNS Number : 2935J
Advanced Oncotherapy PLC
09 April 2020
 

9 April 2020

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

 

Further re Subscription and Issue of Equity in lieu of fees

 

 

Further to the announcement made earlier today, Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that several directors have subscribed for, in aggregate, 760,000   Subscription Shares at the Issue Price as part of the Subscription.

 

Details of the participation by certain directors in the Subscription is set out below.

 

In addition, a number of the Directors have agreed to receive shares in lieu of salaries, fees and bonuses owed, details of which are set out below. This will result in the issue of 825,944 new ordinary shares ("New Ordinary Shares") at the Issue Price. 

 

Director

Number of Subscription Shares

Number of New Ordinary Shares

Michael Sinclair (Executive Chairman)

400,000

265,944

Enrico Vanni (Non-Executive Director)

300,000

120,000

Gabriel Urwitz (Non-Executive Director)

60,000

-

Stephen Myers (Executive Director)

-

200,000

Nick Plowman (Non-Executive Director)

-

120,000

Hans Von Celsing (Non-Executive Director)

-

120,000

 

Further, a number of senior management have agreed to receive shares in lieu of bonuses owed. This will result in the additional issue of 65,542 New Ordinary Shares at the Issue Price.

 

The definitions that apply throughout this announcement are as set out in the announcement made earlier today.  

 

Admission and Total Voting Rights

 

Application will be made for the New Ordinary Shares   to be admitted to trading on AIM and it is expected that admission will take place on or around 15 May 2020 ("Admission").

 

Upon Admission, the Company's enlarged issued share capital will comprise 305,644,992 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights will be 305,644,992.

 

The aforementioned figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Further details and the information required in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 are set out at the end of this announcement.

 

 

- ENDS -

 

Advanced Oncotherapy plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO




Allenby Capital Limited (Nomad & Broker)


Nick Athanas / Liz Kirchner / Nicholas Chambers

Tel: +44 (0) 20 3328 5656



FTI Consulting (Financial PR & IR)

advancedoncotherapy@fticonsulting.com

Simon Conway / Rob Winder

Tel: +44 (0) 20 3727 1000

 

Notes for Editors

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities

a)

Name

PDMRs:

Michael Sinclair

Executive Chairman

Enrico Vanni

Non-Executive Director

Gabriel Urwitz

Non-Executive Director

2

Reason for the notification

a)

Position/status

See 1a) above

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Advanced Oncotherapy plc

b)

LEI

213800LUDHZOG3YT6C82

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 25p each in Advanced Oncotherapy plc

Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109

b)

Nature of the transaction

Participation in a fundraise

 

c)

Price(s) and volume(s)

Price: 25p

 

Volumes:

 

Michael Sinclair

400,000

Enrico Vanni

300,000

Gabriel Urwitz

60,000

 

 

 

d)

Aggregated information

- Aggregated volume

- Price

n/a

e)

Date of the transaction

9 April 2020

 

f)

Place of the transaction

Outside a Trading Venue

 

1

Details of the person discharging managerial responsibilities

a)

Name

PDMRs:

Michael Sinclair

Executive Chairman

Enrico Vanni

Non-Executive Director

Gabriel Urwitz

Non-Executive Director

Nick Plowman

Non-Executive Director

Hans Von Celsing

Non-Executive Director

Stephen Myers

Executive Director

2

Reason for the notification

a)

Position/status

See 1a) above

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Advanced Oncotherapy plc

b)

LEI

213800LUDHZOG3YT6C82

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 25p each in Advanced Oncotherapy plc

Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109

b)

Nature of the transaction

Issue of ordinary shares in consideration of payment of fees/bonuses

 

c)

Price(s) and volume(s)

Price: 25p

 

Volumes:

 

Michael Sinclair

265,944

Enrico Vanni

120,000

Stephen Myers

200,000

Nick Plowman

120,000

Hans Von Celsing

120,000

 

 

 

d)

Aggregated information

- Aggregated volume

- Price

n/a

e)

Date of the transaction

9 April 2020

 

f)

Place of the transaction

Outside a Trading Venue

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FURSSWEEAESSEIL
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close